VLP Therapeutics

About VLP Therapeutics

This author has not yet filled in any details.
So far VLP Therapeutics has created 47 blog entries.

VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer

2014.03.25|

VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-αVLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo") will join VLP as Chair and Chief Medical Officer, effective today.